TITLE

Parathyroid hormone for the treatment of osteoporosis: a systematic review

AUTHOR(S)
Cranney, Ann; Papaioannou, Alexandra; Zytaruk, Nicole; Hanley, David; Adachi, Jonathan; Goltzman, David; Murray, Timothy; Hodsman, Anthony
PUB. DATE
July 2006
SOURCE
CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p52
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Human parathyroid hormone (hPTH)(1-34) was approved in 2004 for the treatment of severe osteoporosis. Members of the Osteoporosis Canada clinical guidelines committee conducted a systematic review of randomized controlled trials (RCTs) to assess the efficacy and safety of hPTH for fracture prevention in postmenopausal women and men with osteoporosis. Methods: We searched MEDLINE, EMBASE, HTA, Current Contents and the Cochrane Controlled Trials Registry for published data from 1966 to February 2005. A systematic literature search for RCTs was conducted using the Cochrane Collaborative approach. We identified 12 trials that randomly assigned patients either to hPTH or placebo or to hPTH or an active comparator and were at least 1 year in duration. Outcomes included change in bone mineral density (BMD), fractures, back pain and adverse events. Two independent reviewers abstracted data on study characteristics and outcomes. Results: hPTH(1-34) significantly increases lumbar spine BMD, with smaller increases at the femoral neck and total hip. hPTH(1-84) significantly increases lumbar spine BMD. The data show a significant reduction in both vertebral and nonvertebral fractures with hPTH(1-34) in postmenopausal women with previous vertebral fractures. There were no data on fractures comparing the approved dose of hPTH(1-34) with active comparators. Interpretation: There is Level I evidence that hPTH(1-34) significantly increases BMD at all skeletal sites except the radius and significantly reduces the risk of new vertebral and nonvertebral fractures in postmenopausal women with prior fractures.
ACCESSION #
21376688

 

Related Articles

  • bmj updates.  // BMJ: British Medical Journal (International Edition);8/12/2006, Vol. 333 Issue 7563, preceding p311 

    The article provides a summary of the article "Parathyroid hormone for the treatment of osteoporosis: a systematic review," by A. Cranney, et al. The study evaluated the use of parathyroid hormone as a treatment for osteoporosis in women. The research found that the use of parathyroid hormone...

  • Recombinant Full-Length Parathyroid Hormone (1-84). Moen, Marit D.; Scott, Lesley J // BioDrugs;2007, Vol. 21 Issue 3, p205 

    The article discusses the importance of recombinant full-length parathyroid hormone in treating osteoporosis. Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation. The resulting loss of bone mass and strength can lead to fragility fractures. Available...

  • Targeting Vascular Niche by Parathyroid Hormone. Pagliarulo, Caterina; Salvatore, Paola; Napoli, Claudio // Current Medicinal Chemistry;2008, Vol. 15 Issue 28, p2984 

    Currently, the parathyroid hormone (PTH) is a drug approved for use in humans only in bone metabolism diseases, as the osteoporosis. The PTH acts primarily by binding to its principal receptor, PTH/PTHrP-R, a member of the class B G protein-coupled receptor (GPCR) family that includes together...

  • Recombinant Full-Length Parathyroid Hormone (1-84): A Viewpoint by James Whitfield. Whitfield, James // Drugs;2006, Vol. 66 Issue 18, p2382 

    â–´ The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer.â–´ Fentanyl is rapidly absorbed from FBT...

  • Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.  // CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p48 

    Focuses on the clinical practice guidelines published by Osteoporosis Canada for the diagnosis and management of osteoporosis in Canada. Evidence for the use of anti-resorptive agents in the management of osteoporosis in 2002; Formation of new bone due to anabolic agents; Review of trials...

  • Effectiveness of teriparatide treatment on back pain-related functional limitations in individuals affected by severe osteoporosis: a prospective pilot study. Iolascon, Giovanni; Gimigliano, Francesca; Malavolta, Nazzarena; Tarantino, Umberto; Fornari, Rachele; Greco, Emanuela; Di Pietro, Gioconda; Gimigliano, Raffaele; Lenzi, Andrea; Resmini, Giuseppina; Migliaccio, Silvia // Clinical Cases in Mineral & Bone Metabolism;Sep-Dec20212, Vol. 9 Issue 3, p161 

    Introduction. Vertebral fractures have been associated with back pain, functional limitations and reduced health-related quality of life (HRQoL). Teriparatide is the first effective anabolic agent that demonstrated to significantly reduce the risk of vertebral fracture by 65%, as compared to...

  • Parathyroid Hormone (1-84) and Risk for Spinal Fractures in Women with Osteoporosis.  // Annals of Internal Medicine;3/6/2007, Vol. 146 Issue 5, pI20 

    The article offers the simplified information concerning parathyroid hormone and risk for spinal fractures in women with osteoporosis to be better understood by patients. It is stated that people with osteoporosis have bones that become less dense and more expected to break. Details regarding...

  • Alternate Treatment for Osteoporosis.  // Infectious Disease Alert;Apr2007, Vol. 26 Issue 7, p2 

    This article discusses findings of a study which focused on recombinant human parathyroid hormone (PTH) as an alternative treatment for osteoporosis. Antiresorptive agents, like bisphosphonates, alendronate and risedronate, are the standard therapy for osteoporosis. PTH is a bone-forming agent,...

  • Therapy of Male Osteoporosis with Parathyroid Hormone. Bilezikian, J.P.; Kurland, E.S. // Calcified Tissue International;Oct2001, Vol. 69 Issue 4, p248 

    Definable causes of male osteoporosis account for only about 60% of the osteoporotic population. Those for whom no etiology is readily apparent are said to have primary or idiopathic male osteoporosis. In these individuals, histomorphometric studies indicate that this is a disorder that is more...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics